Commercial dependence on a limited product base
Most current revenue and strategic value depend on Jelmyto and Zusduri adoption.
- Scope
- Approved products
- Materiality
- high
UroGen Pharma Ltd.
UroGen Pharma Ltd. is a biopharmaceutical company focused on urothelial and specialty cancers, built around its proprietary RTGel reverse-thermal hydrogel platform. The company develops and commercializes local therapies for urinary tract cancers, including approved products Jelmyto and Zusduri, and maintains a pipeline of investigational oncology candidates.
−113,5 %
88,7 %
−139,8 %
+21,4 %
4.01
3.65
| % | |
|---|---|
| Commercial oncology products | 100% Approved therapies sold for non-muscle invasive urothelial cancers. |
| Drug-delivery platform technology | 0% RTGel is used to extend local exposure of drugs in the urinary tract. |
| Clinical-stage pipeline | 0% Investigational programs for additional urothelial and specialty cancers. |
UroGen sells primarily to physicians and healthcare providers treating urothelial cancer, especially urologists and...
- Urologistsprimary
Prescribe Jelmyto and Zusduri for eligible urothelial cancer patients and drive account adoption.
- Oncology practices and cancer centersprimary
Use the products in specialty cancer care settings and support broader physician uptake.
- Payers and reimbursement stakeholderssecondary
Influence patient access through coverage, prior authorization, and reimbursement policies.
- Pharmacies and treatment sitessecondary
Prepare, dispense, and administer the product admixture and support clinical workflow.
UroGen is organized under Israeli law, with principal executive offices in Princeton, New Jersey, and employees in both...
- •Headquartered legally in Israel and operationally in Princeton, New Jersey
- •Commercial sales are concentrated in the United States
- •Employees are split between the U.S. and Israel
- •U.S. market access and reimbursement are central to adoption
- •International commercialization would likely rely on partners
UroGen’s strategy centers on expanding commercialization of Jelmyto and launching Zusduri while advancing its pipeline...
01
Commercialize approved productsshort-term
Revenue and market presence depend on physician adoption and access for Jelmyto and Zusduri.
02
Advance pipeline developmentmedium-term
Future growth depends on expanding the product portfolio beyond current approved therapies.
03
Build commercialization partnerships outside the U.S.medium-term
International markets may require local partners with established sales and distribution networks.
UroGen depends heavily on successful commercialization of a small number of products, so adoption, reimbursement, and...
Financing risk
The company has a history of losses and may need external capital to support operations.
- Scope
- Operations and R&D
- Materiality
- high
Manufacturing and supply-chain risk
Pharmaceutical products rely on contract manufacturers and single-source suppliers.
- Scope
- Jelmyto and pipeline candidates
- Materiality
- high
Regulatory and clinical development risk
Pipeline programs may fail to demonstrate safety, efficacy, or manufacturability.
- Scope
- UGN-501 and other candidates
- Materiality
- high
Reimbursement and physician adoption risk
Specialty oncology products require coverage, formulary access, and workflow integration.
- Scope
- U.S. commercial market
- Materiality
- medium
Net product revenue reserves
Affects reported revenue and gross margin
Inventory write-offs and unit-cost changes
Affects cost of revenue
Debt and prepaid forward obligation accounting
Affects net loss and cash flow interpretation
Acquired asset consideration and royalties
Affects future expense recognition and contingent obligations
PepGen Inc.
PEPG · Pharmaceutical Preparations
Vistagen Therapeutics, Inc.
VTGN · Pharmaceutical Preparations
Vistagen Therapeutics is a U.S.-based clinical-stage biopharmaceutical company focused on neuroscience disorders.
Ultragenyx Pharmaceutical Inc.
RARE · Pharmaceutical Preparations
Neurogene Inc.
NGNE · Pharmaceutical Preparations
enGene Therapeutics Inc.
ENGN · Biological Products, (No Diagnostic Substances)
Ocean Biomedical, Inc.
OCEA · Pharmaceutical Preparations
: 29/04/2026